According to the DataM Intelligence, the global colorectal cancer drugs market size was valued as US$ 12.60 billion in 2024 and is expected to reach US$ 19.96 billion by 2033, growing at a CAGR of 5.2% during the forecast period 2025-2033.
The rise of immunotherapy marks a fundamental transformation in the cancer drugs market, shifting the focus from short-term disease control to long-term survival and improved quality of life. With expanding indications, a growing pipeline of next-generation therapies, and increasing integration of biomarker-driven precision medicine, this segment is poised to remain the most dynamic growth driver in oncology. Companies that prioritize innovation, strategic collaborations, and access strategies will be best positioned to capture market share as immunotherapy continues to redefine global cancer treatment standards.
The global cancer drug market is undergoing a significant shift due to the rapid expansion of immunotherapy, particularly immune checkpoint inhibitors. These therapies stimulate the immune system to recognize and destroy malignant cells, offering longer-lasting responses and improved tolerability. Drugs targeting PD-1, PD-L1, and CTLA-4 pathways have transformed outcomes in melanoma, lung, and colorectal cancer. Increased regulatory approvals, understanding of tumor microenvironments, and biomarker testing are accelerating their adoption.
The momentum in this field is reinforced by a robust pipeline of next-generation therapies that include bispecific antibodies, cancer vaccines, and personalized cell-based treatments. Investment in precision medicine approaches is also rising, as biomarker-driven patient selection improves treatment efficacy and cost-effectiveness.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/colorectal-cancer-drugs-market
Key Highlights from the Report
- North America leads the Colorectal Cancer Drugs market, holding 42.1% share in 2024, driven by strong healthcare systems, major pharmaceutical players like Pfizer and Bristol-Myers Squibb, and active clinical research backed by FDA approvals.
- Chemotherapy remains the leading treatment type, capturing 57.6% share in 2024, supported by FDA-approved regimens and ongoing clinical trials that strengthen its dominance.
- Intravenous is the leading route of administration segment, projected to grow at a 4.5% CAGR, as it provides comprehensive cancer care, advanced technologies, and direct access to branded therapies.
Rising Incidence of Colorectal Cancer driving the market growth
The global burden of colorectal cancer, driven by aging populations, poor diet, sedentary habits, and genetic predispositions, is driving market growth. This trend is boosting the use of chemotherapy, targeted therapies, and immunotherapies, encouraging pharmaceutical companies to invest in innovative drug development and clinical trials.
For instance, according to American Cancer Society,
Colorectal cancer (CRC) is the third most diagnosed cancer in the US and the
third leading cause of cancer death in both men and women. The American Cancer
Society predicts 154,000 new cases in 2025. CRC develops in the soft tissues of
the digestive system, often in the colon or rectum.
By Drug Class - Chemotherapy Segment is expected to leads
the market
Chemotherapy remains the dominant segment in the colorectal
cancer drugs market, accounting for nearly 57.6% share in 2024. The colorectal
cancer market is dominated by chemotherapy segment due to the increasing
incidence of cancer worldwide, aging populations, lifestyle changes, and
environmental factors. Advances in drug formulations and delivery technologies,
as well as a shift towards personalized therapies, have improved treatment
efficacy and patient compliance. Government initiatives, regulatory approvals,
and increased healthcare expenditure further support the adoption of
chemotherapy.
For instance, a recent study shows that combining
Encorafenib and Cetuximab with FOLFOX chemotherapy can extend survival for
patients with BRAF V600E-mutant metastatic colorectal cancer.
Get
Customization in the report as per your requirements: https://www.datamintelligence.com/customize/colorectal-cancer-drugs-market
By Route of Administration – Intravenous is expected to
lead the market with strong growth potential
The intravenous segment led the market and is projected to
register the fastest growth, with a CAGR of 4.5% from 2024 to 2031. The
intravenous (IV) route of administration is the preferred method due to its
rapid and uniform systemic delivery of high-potency chemotherapeutic agents,
particularly in high-dose protocols and combination regimens like FOLFOX.
Advancements in infusion technologies, such as smart pumps with real-time
monitoring and safety features, have improved the precision, safety, and
efficiency of IV chemotherapy, reinforcing its continued preference in cancer
treatment.
North America Colorectal Cancer Drugs Market Trends
North America leads the colorectal cancer drugs market,
holding around 42.1% share, due to its advanced healthcare ecosystem and strong
oncology research environment. Hospitals and treatment centers use advanced
technologies for precise chemotherapy administration. The high cancer prevalence
drives demand for both standard and innovative therapies. Global pharmaceutical
leaders ensure a robust pipeline of new drugs, promoting rapid adoption of
targeted and combination therapies. For instance, in July 2025, PDS
Biotechnology Corporation has completed patient recruitment in Stage 1 of a
clinical trial for metastatic colorectal cancer patients using PDS01ADC
therapeutic, administered systemically in combination with floxuridine, led by
the National Cancer Institute.
Asia-Pacific Colorectal Cancer Drugs Market Trends
The Asia Pacific chemotherapy market is experiencing rapid
growth with around 23.5% due to demographic changes and improved healthcare
access. Rising cancer incidence, urbanization, and lifestyle changes are
driving demand for oncology treatments. Governments in China, India, and Japan
are investing in healthcare infrastructure and promoting advanced treatments.
The expansion of generic and biosimilar drugs is making therapies more
affordable and accessible. For instance, in March 2025, Apollo Hospitals Health
City has launched ColFit, a colorectal cancer screening program, aiming to
improve early detection and prevention. The initiative aims to make colorectal
cancer screening a routine part of healthcare, ensuring early detection and
prevention of the growing threat of colorectal cancer. ColFit not only
diagnoses cancer earlier but also aids in its prevention and curing.
Major Companies:
The
major players in the colorectal cancer drugs market include Roche, Merck &
Co., Inc., Bristol-Myers Squibb, Amgen, Pfizer, Eli Lilly and Company, Bayer,
and Taiho Oncology among others.
Recent Developments: - In August 2025, The FDA has
approved an investigational new drug application for ABT-301, paving the way
for a phase 1/2 clinical trial in combination with Tevimbra and Avastin for
treating metastatic colorectal cancer patients.
- In January 2025, The FDA has approved LUMAKRAS (sotorasib)
in combination with Vectibix (panitumumab) for adult patients with KRAS
G12C-mutated metastatic colorectal cancer (mCRC) who have received prior
chemotherapy. The approval is based on the Phase 3 CodeBreaK 300 study, which
demonstrated that LUMAKRAS plus Vectibix is the first targeted treatment
combination for chemorefractory KRAS G12C-mutated mCRC with superior
progression-free survival compared to standard-of-care.
Related
Reports: 1.
Gastrointestinal
Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031) 2.
Platinum
Based Cancer Drug Market Size, Share, Industry, Forecast and Outlook
(2024-2031) 3.
Breast
Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031) 4.
Skin
Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031) About DataM
Intelligence 4Market Research: DataM
Intelligence 4Market Research is a market intelligence platform that gives
access to syndicated, customized reports and consulting to its clients in one
place. As a firm with rich experience in research and consulting across
multiple domains, we are a one-stop solution that will cater to the needs of
clients in key business areas. DataM Intelligence has an online platform whose
coverage includes industries such as chemicals and materials, agriculture,
health care services, animal feed, and food & beverages among others. Our platform has
Insights on markets that uncover the latest market research data that are
distinct from the competition. With coverage across 10 major industries in the
marketplace research, DataM Intelligence benefits thousands of companies by
helping them take their innovations early to the market, by providing a
complete view of the market with statistical forecasts. Our strategy-centric
framework and value-added services will let individuals and corporates with
ease of access and custom personalization to research and markets. To find out more,
visit https://www.datamintelligence.com/ or follow us onTwitter,
LinkedIn
and Facebook. Contact: Mr. Sai Kiran Visit Our
Website:https://www.datamintelligence.com/
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email:Sai.k@datamintelligence.com
Content Source: https://www.datamintelligence.com/research-report/colorectal-cancer-drugs-market
